Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

NCT04348006 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No patients were enrolled in the study

Conditions

Newly Diagnosed Multiple Myeloma

Interventions

DRUG: Bortezomib 3.5 MG

Sponsor

Al-Rasheed University College

Collaborators

[object Object]